NCT05367297

Brief Summary

Individuals who self-report as SAs will be recruited to participate in this registry as well as non-SA controls for comparison. All individuals who consent to participate will 1) complete a survey assessing demographics, medical history, family medical history; 2) have blood collection; 3) and CCTA assessment. These data will be combined with clinical data from the electronic health record and, if applicable, the Dallas Hearts and Mind Study and other research studies, for research purposes. The registry will serve to generate primary observations as well as preliminary data for future studies.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
12mo left

Started Jun 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Jun 2022Apr 2027

First Submitted

Initial submission to the registry

April 12, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

May 10, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

June 15, 2022

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2027

Last Updated

August 28, 2025

Status Verified

August 1, 2025

Enrollment Period

4.9 years

First QC Date

April 12, 2022

Last Update Submit

August 21, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number and type of adverse and protective CTA-derived plaque features Number and type of adverse and protective CTA-derived plaque features

    There will be several features derived from CTA that are validated adverse features, including plaque volume, thin cap, low attenuation, and necrotic core. Protective features include fibrous cap thickness.

    Day 1

Interventions

Coronary CT AngiogramDIAGNOSTIC_TEST

A computerized tomography (CT) coronary angiogram is non-invasive imaging test that looks at the arteries that supply blood to your heart.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults with South Asian descent (South Asians to have both biological parents with ancestry from India, Pakistan, Sri Lanka, Nepal and Bangladesh) and non South Asian Adult volunteers (age 18 years or older).

You may qualify if:

  • Males and Females: Age 18 years or above
  • South Asian (SA) adults through self-identification (South Asians to have both biological parents with ancestry from India, Pakistan, Sri Lanka, Nepal and Bangladesh)
  • We also propose to enroll an equivalent number of individuals of other descent as a comparator group (Non SA Adult Volunteers)
  • Sampling Method: Probability Sample

You may not qualify if:

  • Under the age of 18 years
  • Unable to give informed consent
  • Impaired renal function: estimated glomerular filtration rate ≤ 45ml/min
  • Baseline heart rate≥70 bpm or ≥66 bpm after beta blocker
  • Body mass index (BMI) of 35 or greater
  • Prior anaphylactic/non-anaphylactic reaction or other contraindication to iodinated contrast
  • Anyone who cannot do CCTA for any reason
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

RECRUITING

MeSH Terms

Conditions

Coronary Artery DiseaseHeart Diseases

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Anand Rohatgi, MD

    University of Texas Southwestern Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine

Study Record Dates

First Submitted

April 12, 2022

First Posted

May 10, 2022

Study Start

June 15, 2022

Primary Completion (Estimated)

April 30, 2027

Study Completion (Estimated)

April 30, 2027

Last Updated

August 28, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will share

Deidentified demographics, risk factors, clinical history, and research-based measures will be shared with other researchers with appropriate approval.

Shared Documents
STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
Time Frame
Data will become available after completed enrollment of any participant. The data will be available for the duration of the registry.
Access Criteria
Researchers may request data from the PI, Dr. Anand Rohatgi. Once approval is given and appropriate regulatory approvals are in place, access may be granted and data shared.

Locations